Barclays PLC Has $934,000 Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Barclays PLC increased its position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 32.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 494,516 shares of the company’s stock after buying an additional 121,799 shares during the period. Barclays PLC’s holdings in Mersana Therapeutics were worth $934,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. US Bancorp DE acquired a new position in shares of Mersana Therapeutics during the third quarter valued at about $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Mersana Therapeutics in the 3rd quarter worth about $34,000. Intech Investment Management LLC bought a new position in Mersana Therapeutics in the 3rd quarter valued at about $52,000. Quarry LP acquired a new position in Mersana Therapeutics during the 3rd quarter valued at about $57,000. Finally, Algert Global LLC bought a new stake in Mersana Therapeutics during the 2nd quarter worth approximately $90,000. 93.92% of the stock is owned by institutional investors.

Mersana Therapeutics Stock Performance

Shares of Mersana Therapeutics stock opened at $0.63 on Wednesday. The business’s fifty day simple moving average is $1.95 and its 200 day simple moving average is $1.87. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $6.28. The firm has a market capitalization of $78.32 million, a P/E ratio of -1.04 and a beta of 1.43.

Mersana Therapeutics (NASDAQ:MRSN) last released its earnings results on Wednesday, November 13th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. The company had revenue of $12.60 million for the quarter, compared to analysts’ expectations of $7.53 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The business’s revenue for the quarter was up 63.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.35) EPS. As a group, analysts anticipate that Mersana Therapeutics, Inc. will post -0.61 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MRSN. Citigroup started coverage on Mersana Therapeutics in a report on Friday, November 15th. They issued a “buy” rating and a $5.00 target price on the stock. Wedbush restated an “outperform” rating and set a $4.00 price objective (down from $7.00) on shares of Mersana Therapeutics in a research note on Friday, January 10th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $5.57.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.